XERS News and Press, Xeris Pharmaceuticals Inc. From 11/02/22

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that th...

First prospective long-term levoketoconazole study demonstrating a sustained effect on cortisol levels, as well as improvements in biomarkers of Cushing’s syndrome (CS) comorbidity, clinical signs and symptoms of CS and quality of life (QoL). With a median treatment...

Penny Stocks To Buy Now? Are you looking for penny stocks to buy now? If your answer is “yes,” you’re not alone. But before you dive headfirst into something someone on Reddit posted, you’ll want to make sure to do a few things first. For starters, find the t...

Xeris Biopharma Holdings ( NASDAQ: XERS ) said its once weekly subcutaneous (SC) injection of levothyroxine (XP-8121) showed similar exposure at steady-state as daily oral levothyroxine (Synthroid) in a phase 1 trial in healthy people. The data supports further developme...

Data demonstrate proof-of-concept showing a once weekly subcutaneous injection of XP-8121 provides similar exposure at steady-state as daily oral Synthroid® Simulation model implies dose conversion factor of 4X XP-8121 in healthy volunteers was generally well tole...

Today, we take a look at Xeris Biopharma Holdings which has three products on the market. The company is seeing solid revenue growth and management projects Xeris will be at cash flow breakeven status by the end of 2023. An investment analysis follows in the paragraphs below. ...

Xeris Biopharma Holdings, Inc. (XERS) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations and Corporate Communications Paul Edick - Chairman and Chief Executive Officer Steve P...

Xeris ( NASDAQ: XERS ) Pharmaceuticals saw its Q2 2022 net loss narrow ~4% to $26.2M as the biotech beat on the bottom line . Although revenue of ~$320M was a ~49% year-over-year increase, it was a slight miss. Sales of the company's biggest selling product, Gvoke ...

Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q2 GAAP EPS of -$0.19 beats by $0.04 . Revenue of $25.31M (+184.1% Y/Y) misses by $0.22M . Ended Q2 with $111.6M in cash, cash equivalents and short-term investments For further details see: Xeris ...

Achieved record net product revenue of $25.3M – a 15% increase from Q1 ’22, and a 34% increase from same period prior year on a pro forma basis Ended Q2 with $111.6M in cash, cash equivalents and short-term investments Reaffirms full-year total net produc...